FRI0345 Neurological Manifestations of Primary Sjögren Syndrome
BackgroundPrimary Sjögren syndrome (pSS) is a chronic systemic autoimmune disease with a relevant impact in patients' quality of life. Neurological manifestations of pSS could have an important impact on morbidity and mortality.ObjectivesThe aim of our study was to evaluate central and peripher...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.559-560 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 560 |
|---|---|
| container_issue | Suppl 2 |
| container_start_page | 559 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 75 |
| creator | Fernandez Castro, M. Andreu, J.L. Sanchez-Piedra, C. Rosas, J. Martinez Taboada, V. Olive, A. |
| description | BackgroundPrimary Sjögren syndrome (pSS) is a chronic systemic autoimmune disease with a relevant impact in patients' quality of life. Neurological manifestations of pSS could have an important impact on morbidity and mortality.ObjectivesThe aim of our study was to evaluate central and peripheral neurological manifestations of a pSS cohort of patients assisted in Spanish Reumathology Departments.MethodsThis is a multicentre descriptive transversal study of pSS patients from thirty-three rheumatology departments. Patients fulfilling European/American consensus criteria were included after randomisation. By reviewing clinical records and interviewing the patients, we collected epidemiological, clinical, serologic, therapeutic, and disease activity indexes data. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates. Chi-square was used to establish the statistical associations, being considered a p |
| doi_str_mv | 10.1136/annrheumdis-2016-eular.3879 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1902055303</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322516759</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1273-2e2da82e844dea11529e373d8988d1064ab2615d70a0d5279f7490f61d8476a33</originalsourceid><addsrcrecordid>eNqVkE1OwzAQhS0EEqVwh0hdp4x_YjtiBRUtlcqPKKwtt3ZKoiQudrPojg1X4gLchJOQEBZsWY3e6L2Zpw-hEYYxxpSf67r2L7apTB5iApjHtim1H1Mp0gM0wIzLds3hEA0AgMYs5eIYnYRQtBIklgN0NX2cA2XJ19v7nW28K90mX-syutV1ntmw07vc1SFyWfTg80r7fbQsPj823tbRcl8b7yp7io4yXQZ79juH6Hl6_TS5iRf3s_nkchGvMBE0JpYYLYmVjBmrMU5IaqmgRqZSGgyc6RXhODECNJiEiDQTLIWMYyOZ4JrSIRr1d7fevTZtN1W4xtftS4VTIJAkFDrXRe9aexeCt5na9sUVBtVBU3-gqQ6a-oGmOmhtmvfpVVX8K_gNs094PQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1902055303</pqid></control><display><type>article</type><title>FRI0345 Neurological Manifestations of Primary Sjögren Syndrome</title><source>BMJ Journals - NESLi2</source><creator>Fernandez Castro, M. ; Andreu, J.L. ; Sanchez-Piedra, C. ; Rosas, J. ; Martinez Taboada, V. ; Olive, A.</creator><creatorcontrib>Fernandez Castro, M. ; Andreu, J.L. ; Sanchez-Piedra, C. ; Rosas, J. ; Martinez Taboada, V. ; Olive, A.</creatorcontrib><description>BackgroundPrimary Sjögren syndrome (pSS) is a chronic systemic autoimmune disease with a relevant impact in patients' quality of life. Neurological manifestations of pSS could have an important impact on morbidity and mortality.ObjectivesThe aim of our study was to evaluate central and peripheral neurological manifestations of a pSS cohort of patients assisted in Spanish Reumathology Departments.MethodsThis is a multicentre descriptive transversal study of pSS patients from thirty-three rheumatology departments. Patients fulfilling European/American consensus criteria were included after randomisation. By reviewing clinical records and interviewing the patients, we collected epidemiological, clinical, serologic, therapeutic, and disease activity indexes data. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates. Chi-square was used to establish the statistical associations, being considered a p<0.05 as significant.ResultsFour hundred and thirty-seven patients were included. Ninety five percent of them were women. The median age of the cohort was 58 years. Thirty-four (7.8%) patients developed central nervous system (CNS) involvement. Interestingly, 15 patients developed CNS manifestations before the diagnosis of pSS. Fourteen patients referred headache, 11 patients some psychiatric disorder, 6 patients cerebral ischemic attack, 5 patients cognitive impairment, 5 patients multiple sclerosis, 3 patients cranial nerve involvement of central origin, 3 patients cerebral vasculitis, 2 patients optic neuritis, a patient aseptic meningitis and a patient myelopathy. ESSDAI index was significantly higher in patients with CNS involvement. Systemic treatments (glucocorticoids, bolus of glucocorticoids, azathioprine, methotrexate and cyclophosphamide) and biological treatments (anti-TNF, abatacept and tocilizumab) were used significantly more frequently in patients with CNS impairment. Thirty-nine (8.9%) patients developed peripheral nervous system (PNS) involvement, 14 of them, before the diagnosis of pSS. Thirteen patients had mixed polyneuropathy, 2 patients motor polyneuropathy, 8 patients sensitive polyneuropathy, 3 patients small fiber neuropathy, a patient developed mononeuritis multiplex and 8 patients focal mononeuropathy. Three patients had trigeminal sensory neuropathy, a patient III cranial neuropathy and 3 patients VII cranial neuropathy. SSDAI and ESSDAI indexes were significantly higher in patients with PNS involvement. Systemic therapies (glucocorticoids, bolus of glucocorticoids, methotrexate, mycophenolate mofetil and cyclophosphamide), biological treatments (rituximab) and intravenous immunoglobulins were used significantly more frequently in patients with PNS impairment.ConclusionsMore than 7% of pSS patients with pSS of our cohort developed nervous system manifestations. The CNS and PNS involvement led to a significantly higher disease activity, scored by formal activity indexes. The use of systemic and biological treatment was significantly higher in patients with nervous system involvement.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.3879</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.559-560</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/559.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/559.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Fernandez Castro, M.</creatorcontrib><creatorcontrib>Andreu, J.L.</creatorcontrib><creatorcontrib>Sanchez-Piedra, C.</creatorcontrib><creatorcontrib>Rosas, J.</creatorcontrib><creatorcontrib>Martinez Taboada, V.</creatorcontrib><creatorcontrib>Olive, A.</creatorcontrib><title>FRI0345 Neurological Manifestations of Primary Sjögren Syndrome</title><title>Annals of the rheumatic diseases</title><description>BackgroundPrimary Sjögren syndrome (pSS) is a chronic systemic autoimmune disease with a relevant impact in patients' quality of life. Neurological manifestations of pSS could have an important impact on morbidity and mortality.ObjectivesThe aim of our study was to evaluate central and peripheral neurological manifestations of a pSS cohort of patients assisted in Spanish Reumathology Departments.MethodsThis is a multicentre descriptive transversal study of pSS patients from thirty-three rheumatology departments. Patients fulfilling European/American consensus criteria were included after randomisation. By reviewing clinical records and interviewing the patients, we collected epidemiological, clinical, serologic, therapeutic, and disease activity indexes data. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates. Chi-square was used to establish the statistical associations, being considered a p<0.05 as significant.ResultsFour hundred and thirty-seven patients were included. Ninety five percent of them were women. The median age of the cohort was 58 years. Thirty-four (7.8%) patients developed central nervous system (CNS) involvement. Interestingly, 15 patients developed CNS manifestations before the diagnosis of pSS. Fourteen patients referred headache, 11 patients some psychiatric disorder, 6 patients cerebral ischemic attack, 5 patients cognitive impairment, 5 patients multiple sclerosis, 3 patients cranial nerve involvement of central origin, 3 patients cerebral vasculitis, 2 patients optic neuritis, a patient aseptic meningitis and a patient myelopathy. ESSDAI index was significantly higher in patients with CNS involvement. Systemic treatments (glucocorticoids, bolus of glucocorticoids, azathioprine, methotrexate and cyclophosphamide) and biological treatments (anti-TNF, abatacept and tocilizumab) were used significantly more frequently in patients with CNS impairment. Thirty-nine (8.9%) patients developed peripheral nervous system (PNS) involvement, 14 of them, before the diagnosis of pSS. Thirteen patients had mixed polyneuropathy, 2 patients motor polyneuropathy, 8 patients sensitive polyneuropathy, 3 patients small fiber neuropathy, a patient developed mononeuritis multiplex and 8 patients focal mononeuropathy. Three patients had trigeminal sensory neuropathy, a patient III cranial neuropathy and 3 patients VII cranial neuropathy. SSDAI and ESSDAI indexes were significantly higher in patients with PNS involvement. Systemic therapies (glucocorticoids, bolus of glucocorticoids, methotrexate, mycophenolate mofetil and cyclophosphamide), biological treatments (rituximab) and intravenous immunoglobulins were used significantly more frequently in patients with PNS impairment.ConclusionsMore than 7% of pSS patients with pSS of our cohort developed nervous system manifestations. The CNS and PNS involvement led to a significantly higher disease activity, scored by formal activity indexes. The use of systemic and biological treatment was significantly higher in patients with nervous system involvement.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkE1OwzAQhS0EEqVwh0hdp4x_YjtiBRUtlcqPKKwtt3ZKoiQudrPojg1X4gLchJOQEBZsWY3e6L2Zpw-hEYYxxpSf67r2L7apTB5iApjHtim1H1Mp0gM0wIzLds3hEA0AgMYs5eIYnYRQtBIklgN0NX2cA2XJ19v7nW28K90mX-syutV1ntmw07vc1SFyWfTg80r7fbQsPj823tbRcl8b7yp7io4yXQZ79juH6Hl6_TS5iRf3s_nkchGvMBE0JpYYLYmVjBmrMU5IaqmgRqZSGgyc6RXhODECNJiEiDQTLIWMYyOZ4JrSIRr1d7fevTZtN1W4xtftS4VTIJAkFDrXRe9aexeCt5na9sUVBtVBU3-gqQ6a-oGmOmhtmvfpVVX8K_gNs094PQ</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Fernandez Castro, M.</creator><creator>Andreu, J.L.</creator><creator>Sanchez-Piedra, C.</creator><creator>Rosas, J.</creator><creator>Martinez Taboada, V.</creator><creator>Olive, A.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>FRI0345 Neurological Manifestations of Primary Sjögren Syndrome</title><author>Fernandez Castro, M. ; Andreu, J.L. ; Sanchez-Piedra, C. ; Rosas, J. ; Martinez Taboada, V. ; Olive, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1273-2e2da82e844dea11529e373d8988d1064ab2615d70a0d5279f7490f61d8476a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernandez Castro, M.</creatorcontrib><creatorcontrib>Andreu, J.L.</creatorcontrib><creatorcontrib>Sanchez-Piedra, C.</creatorcontrib><creatorcontrib>Rosas, J.</creatorcontrib><creatorcontrib>Martinez Taboada, V.</creatorcontrib><creatorcontrib>Olive, A.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernandez Castro, M.</au><au>Andreu, J.L.</au><au>Sanchez-Piedra, C.</au><au>Rosas, J.</au><au>Martinez Taboada, V.</au><au>Olive, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FRI0345 Neurological Manifestations of Primary Sjögren Syndrome</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>559</spage><epage>560</epage><pages>559-560</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundPrimary Sjögren syndrome (pSS) is a chronic systemic autoimmune disease with a relevant impact in patients' quality of life. Neurological manifestations of pSS could have an important impact on morbidity and mortality.ObjectivesThe aim of our study was to evaluate central and peripheral neurological manifestations of a pSS cohort of patients assisted in Spanish Reumathology Departments.MethodsThis is a multicentre descriptive transversal study of pSS patients from thirty-three rheumatology departments. Patients fulfilling European/American consensus criteria were included after randomisation. By reviewing clinical records and interviewing the patients, we collected epidemiological, clinical, serologic, therapeutic, and disease activity indexes data. Informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates. Chi-square was used to establish the statistical associations, being considered a p<0.05 as significant.ResultsFour hundred and thirty-seven patients were included. Ninety five percent of them were women. The median age of the cohort was 58 years. Thirty-four (7.8%) patients developed central nervous system (CNS) involvement. Interestingly, 15 patients developed CNS manifestations before the diagnosis of pSS. Fourteen patients referred headache, 11 patients some psychiatric disorder, 6 patients cerebral ischemic attack, 5 patients cognitive impairment, 5 patients multiple sclerosis, 3 patients cranial nerve involvement of central origin, 3 patients cerebral vasculitis, 2 patients optic neuritis, a patient aseptic meningitis and a patient myelopathy. ESSDAI index was significantly higher in patients with CNS involvement. Systemic treatments (glucocorticoids, bolus of glucocorticoids, azathioprine, methotrexate and cyclophosphamide) and biological treatments (anti-TNF, abatacept and tocilizumab) were used significantly more frequently in patients with CNS impairment. Thirty-nine (8.9%) patients developed peripheral nervous system (PNS) involvement, 14 of them, before the diagnosis of pSS. Thirteen patients had mixed polyneuropathy, 2 patients motor polyneuropathy, 8 patients sensitive polyneuropathy, 3 patients small fiber neuropathy, a patient developed mononeuritis multiplex and 8 patients focal mononeuropathy. Three patients had trigeminal sensory neuropathy, a patient III cranial neuropathy and 3 patients VII cranial neuropathy. SSDAI and ESSDAI indexes were significantly higher in patients with PNS involvement. Systemic therapies (glucocorticoids, bolus of glucocorticoids, methotrexate, mycophenolate mofetil and cyclophosphamide), biological treatments (rituximab) and intravenous immunoglobulins were used significantly more frequently in patients with PNS impairment.ConclusionsMore than 7% of pSS patients with pSS of our cohort developed nervous system manifestations. The CNS and PNS involvement led to a significantly higher disease activity, scored by formal activity indexes. The use of systemic and biological treatment was significantly higher in patients with nervous system involvement.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2016-eular.3879</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.559-560 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_journals_1902055303 |
| source | BMJ Journals - NESLi2 |
| title | FRI0345 Neurological Manifestations of Primary Sjögren Syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A23%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FRI0345%E2%80%85Neurological%20Manifestations%20of%20Primary%20Sj%C3%B6gren%20Syndrome&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Fernandez%20Castro,%20M.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=559&rft.epage=560&rft.pages=559-560&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.3879&rft_dat=%3Cproquest_cross%3E4322516759%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1902055303&rft_id=info:pmid/&rfr_iscdi=true |